U.S. pharma big copyright scrapped two experimental weight loss pills previous year—a after-every day tablet, lotiglipron, due to elevated liver enzymes along with a two times-day-to-day pill, danuglipron, due to strong Unwanted side effects—but CEO Albert Bourla has claimed the comp